Industry Briefs: May 14, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: May 14, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Almac has added the new PharmaWorks TF3, high-speed, large-format blister equipment, at its US headquarters in Souderton, Pennsylvania. Read More

GE Healthcare Life Sciences has completed its acquisition of Xcellerex. Read More

Molecular Profiles and GEA Process Engineering are collaborating to improve early screening of poorly water-soluble drugs and polymer compositions using the GEA Niro Drynetics single-particle spray-drying application.

Novozymes Biopharma has started to supply Novozymes Hyasis, a pharmaceutical-grade hyaluronic acid, from its recently opened facility in Tianjin, China. Read More

NSF-DBA has agreed with the Semler Research Center to expand pharmaceutical training, auditing, consulting, and testing services throughout India. Read More

People News

Cytovance Biologics has named Martin LeBlanc to its board of directors. Read More

Incline Therapeutics has appointed John Tucker as senior vice-president and chief commercial officer. Read More

Teva Pharmaceutical has appointed Michael Hayden as president of global R&D and chief scientific officer Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here